Since pulmonary aspiration risk is strongly influenced by baseline patient characteristics, factors such as indications for GLP-1 agonist use (e.g., diabetes and obesity) and underlying comorbidities like GERD and autonomic neuropathy may also contribute to the observed heterogeneity. Here, GLP1R is linked to obesity disorder.